A groundbreaking $1.76 billion syndicated loan has been secured for the world's largest flying car project, marking a major shift in technology financing. This patient capital approach is designed to support long-term, high-tech growth, moving beyond traditional lending models that only accept land and factory assets.
Guangzhou's "Land Aircraft Carrier"—a flying car venture—has invested billions in research and development, with 7,000 confirmed orders pending. The construction of its mass production facility is urgent, yet the company lacks sufficient collateral, and the industry has no precedent for financing. To address this, a syndicate of banks has provided a $1.76 billion special loan, phased to support the base's construction and accelerate order fulfillment. The local branch alone has served 220 technology companies, with a loan balance exceeding $15.4 billion.
A "technology-flow" evaluation system has enabled a precision manufacturing giant in Chongqing to speed up its upgrade. This company, specializing in notebook components and generating over $1.4 billion in annual revenue, spends tens of millions yearly on equipment and R&D but has exhausted its collateral assets. By assessing patents, R&D teams, and industry standing, the bank approved and disbursed a $3.5 million credit line within three days to upgrade production lines. The new laser-cutting technology doubled efficiency, and the company's patents surged from a dozen to nearly 200, allowing it to enter the medical equipment sector.
In Shenzhen, a specialized protective eyewear company—a "hidden champion"—secured a $3.75 million loan in just one week, saving a major order for military-grade goggles. With no factory or heavy assets, the city's technology finance model broke conventional barriers. Using a smart scoring system based on patents and R&D qualifications, the bank approved the loan, preserving a large order for a product identical to those used in military parades. Now, finance institutions no longer fixate on fixed assets; patents, R&D teams, and industry prospects are core criteria. Committed to early-stage, small-scale, and long-term investments, patient capital is clearing financing bottlenecks for technology innovation, injecting liquidity into the modern industrial system for the 15th Five-Year Plan period.
Comments